A Multicenter, Single-arm, Phase II Exploratory Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line Anticancer Agent in NSCLC Patients With EGFR Mutation
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Dec 2016
At a glance
- Drugs Olmutinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Hanmi Pharmaceutical
- 02 Feb 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Dec 2016 as reported by Clinicaltrials.gov record.
- 02 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by Clinicaltrials.gov record.
- 19 Nov 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Jun 2016 as per ClinicalTrials.gov record.